BioRestorative Therapies, Inc. (BRTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioRestorative Therapies, Inc. (BRTX) Healthcare & Pipeline Overview

BioRestorative Therapies, Inc. is a life sciences company advancing regenerative medicine through adult stem cell therapies. Its primary programs target disc/spine disease with BRTX-100, which has completed Phase 1 trials, and metabolic disorders via the preclinical ThermoStem program. The company also develops a specialized curved needle device, leveraging strategic research collaborations.

What Is the Investment Thesis for BRTX?

BioRestorative Therapies, Inc. presents an investment thesis centered on its early-stage regenerative medicine pipeline and strategic collaborations. The company's lead candidate, BRTX-100, having successfully completed Phase 1 clinical trials for painful lumbosacral disc disorders, represents a significant value driver. Progression into Phase 2 trials would be a critical de-risking event and a key catalyst, potentially unlocking a substantial market for non-surgical spinal treatments. The investigational curved needle device further enhances the delivery mechanism for such therapies. The preclinical ThermoStem program, targeting obesity and metabolic disorders, offers additional long-term growth potential in a vast and underserved market, leveraging brown adipose derived stem cells. Strategic research and development agreements with industry leaders like Rohto Pharmaceutical and Pfizer, alongside academic collaboration with the University of Pennsylvania, provide external validation and potential pathways for future development and commercialization. While the company currently reports a negative profit margin of -3089.6% and a market capitalization of $3.81M, typical for a pre-revenue biotechnology firm, its reported gross margin of 92.1% suggests strong potential profitability if products reach commercialization. The low beta of 0.20 indicates relatively low volatility compared to the broader market, though this can be characteristic of early-stage, news-driven biotech stocks. Future value creation is highly dependent on successful clinical trial outcomes and regulatory approvals for its innovative cell therapies.

Based on FMP financials and quantitative analysis

BRTX Key Highlights

BRTX-100, the lead cell therapy candidate, has successfully completed Phase 1 clinical trials for lumbosacral disc disorders, marking a significant developmental milestone.

• The company maintains a high gross margin of 92.1%, indicating strong potential profitability on any future revenue streams from its intellectual property or commercialized products.
• BioRestorative Therapies operates with a lean structure, employing 11 individuals, which is typical for a specialized biotechnology company focused on R&D.
• Strategic research and development agreements are in place with major pharmaceutical entities like Pfizer, Inc. and Rohto Pharmaceutical Co., Ltd., validating its research focus.
• The Metabolic Program (ThermoStem) is advancing through preclinical stages, targeting large markets such as obesity and metabolic disorders with a novel cell-based therapy.

Who Are BRTX's Competitors?

BRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BRTX's Key Strengths?

Lead candidate BRTX-100 has successfully completed Phase 1 clinical trials for disc/spine disease.

• Strategic research and development partnerships with major pharmaceutical companies (Pfizer, Rohto) and academic institutions (University of Pennsylvania).
• Proprietary investigational curved needle device for targeted therapeutic delivery to the spine and discs.
• Focus on high-need therapeutic areas with significant market potential (disc/spine disease, metabolic disorders).

What Are BRTX's Weaknesses?

Early-stage pipeline with lead candidate BRTX-100 having only completed Phase 1, and ThermoStem in preclinical stages.

• Negative profit margin of -3089.6% and a market capitalization of $3.81M, typical for a pre-revenue biotechnology company.
• A relatively small employee base of 11, which may limit the pace of multiple large-scale clinical programs.
• High dependence on successful clinical trial outcomes and regulatory approvals for future commercial viability.

What Could Drive BRTX Stock Higher?

BRTX catalyst: Initiation of Phase 2 clinical trials for BRTX-100 for the treatment of lumbosacral disc disorders.

• Advancement of the ThermoStem program into human clinical trials for obesity and metabolic disorders.
• Announcement of new or expanded research and development partnerships with major pharmaceutical companies.
• Achievement of significant regulatory milestones or approvals for the investigational curved needle device.
• Continued progress in preclinical development for the ThermoStem program and other potential pipeline candidates.

What Are the Key Risks for BRTX?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures or unexpected adverse events for BRTX-100 or ThermoStem, leading to delays or discontinuation of development.
• Inability to secure sufficient additional funding to finance ongoing and future clinical development and operational expenses.
• Intense competition within the regenerative medicine and biotechnology sectors from companies with greater financial and research resources.
• Regulatory delays or failure to obtain necessary approvals from health authorities for product commercialization.
• Challenges related to intellectual property protection, including patent disputes or the inability to maintain exclusive rights to its technologies.

What Are the Growth Opportunities for BRTX?

• **Advancement of BRTX-100 into later-stage clinical trials and eventual commercialization:** The successful completion of Phase 1 clinical trials for BRTX-100, targeting painful lumbosacral disc disorders, represents a foundational step. The global market for spinal disorder treatments is substantial, with a growing demand for non-surgical, regenerative options. Progression into Phase 2 and Phase 3 trials, followed by regulatory approval, would unlock access to a significant patient population seeking alternatives to invasive surgery. BRTX-100's autologous nature, utilizing a patient's own stem cells, offers a potential competitive advantage by reducing immune rejection risks and aligning with personalized medicine trends. The timeline for this opportunity spans several years, contingent on trial outcomes and regulatory pathways.
• **Successful development and commercialization of the ThermoStem program for metabolic disorders:** The ThermoStem program, currently in preclinical stages, targets the vast and growing markets of obesity and metabolic disorders. These conditions represent a global health crisis, driving demand for innovative therapeutic solutions. By leveraging brown adipose derived stem cells to generate brown adipose tissue, ThermoStem aims to address the underlying metabolic dysregulation. Successful progression through clinical development and regulatory approval could position BioRestorative Therapies as a leader in a novel approach to metabolic health. The market potential is enormous, with billions of dollars spent annually on managing these conditions, offering a long-term growth trajectory if the therapy proves safe and effective.
• **Expansion and leveraging of strategic research and development partnerships:** BioRestorative Therapies has established key collaborations with entities such as Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. These partnerships provide not only external validation of the company's scientific approach but also access to additional resources, expertise, and potential funding. Expanding these relationships or forging new ones could accelerate research, de-risk development, and provide pathways for broader market access or licensing agreements for its therapeutic candidates and delivery device. Such collaborations are crucial in the capital-intensive biotechnology industry, offering a competitive edge through shared risk and enhanced capabilities, potentially shortening development timelines and increasing commercialization prospects.
• **Commercialization or licensing of the investigational curved needle device:** Beyond its cell therapies, BioRestorative Therapies possesses an investigational curved needle device designed for precise delivery of therapeutic products to the spine and discs. This device could represent a standalone revenue stream through direct sales or licensing agreements to other companies developing spinal therapies. The market for specialized medical devices, particularly those enhancing drug or cell delivery in complex anatomical areas like the spine, is significant. This proprietary technology offers a competitive advantage by potentially improving the efficacy and safety of various spinal treatments, extending beyond BioRestorative Therapies' own pipeline and providing a diversified revenue opportunity.
• **Exploration and expansion into additional therapeutic indications:** The underlying adult stem cell technology and expertise developed by BioRestorative Therapies for its brtxDisc and ThermoStem programs could be applicable to a broader range of diseases beyond current targets. Regenerative medicine has potential across numerous therapeutic areas, including orthopedics, neurology, and cardiology. By strategically identifying new indications where its cell and tissue protocols could offer significant clinical benefits, the company could diversify its pipeline and tap into additional large markets. This expansion would leverage existing scientific knowledge and intellectual property, potentially creating new growth avenues and increasing the overall value proposition of the company's platform technology over the long term.

What Threats Does BRTX Face?

• High risk of clinical trial failures, delays, or unexpected adverse events for its therapeutic candidates.
• Intense competition from larger, well-funded pharmaceutical and biotechnology companies in regenerative medicine.
• Significant regulatory hurdles and lengthy approval processes inherent to novel cell therapies.
• Need for substantial and continuous capital investment to fund extensive research, development, and clinical trials.

What Are BRTX's Competitive Advantages?

• Proprietary cell therapy candidates, BRTX-100 and ThermoStem, represent unique approaches in regenerative medicine for specific indications.
• The investigational curved needle device offers a specialized and potentially patented solution for targeted delivery to the spine and discs.
• Strategic research and development agreements with established pharmaceutical companies like Pfizer and Rohto provide validation and potential for co-development.
• Expertise in isolating, culturing, and applying adult stem cells for therapeutic purposes, particularly autologous mesenchymal stem cells and brown adipose derived stem cells.
• Intellectual property surrounding its cell protocols, therapeutic compositions, and delivery technologies provides a barrier to entry for competitors.

What Does BRTX Do?

BioRestorative Therapies, Inc., established in 1997 and headquartered in Melville, New York, is a pioneering life sciences company dedicated to the advancement of regenerative medicine. Initially incorporated as Stem Cell Assurance, Inc., the company rebranded in August 2011 to its current name, reflecting its evolving focus on restorative therapies. With a lean team of 11 employees, BioRestorative Therapies specializes in developing innovative products and therapies utilizing cell and tissue protocols, with a primary emphasis on adult stem cells. The company's strategic pipeline is anchored by two distinct yet critical developmental programs: the brtxDisc program, targeting disc/spine disease, and the Metabolic Program (ThermoStem), addressing metabolic disorders. The brtxDisc program features its lead cell therapy candidate, BRTX-100, an autologous product derived from cultured mesenchymal stem cells. These cells are meticulously collected from the patient's own bone marrow, ensuring a personalized therapeutic approach. BRTX-100 has successfully completed Phase 1 clinical trials, demonstrating its potential for the non-surgical treatment of painful lumbosacral disc disorders, a condition affecting millions globally. This advancement positions BRTX-100 as a promising candidate in the growing field of non-invasive spinal therapies. Concurrently, BioRestorative Therapies is developing its Metabolic Program, known as ThermoStem. This cell-based therapy candidate is currently in the preclinical stage and aims to combat obesity and various metabolic disorders. ThermoStem leverages brown adipose derived stem cells to generate brown adipose tissue, which is known for its role in energy expenditure and metabolic regulation. This innovative approach seeks to harness the body's natural mechanisms to address complex metabolic challenges. Beyond its therapeutic candidates, the company also provides an investigational curved needle device. This specialized instrument is designed to precisely deliver cells and/or other therapeutic products or materials directly to the spine and discs, enhancing the efficacy and safety of targeted treatments. BioRestorative Therapies has strategically forged significant research and development partnerships, including an agreement with Rohto Pharmaceutical Co., Ltd., a research agreement with Pfizer, Inc., and a research collaboration agreement with the University of Pennsylvania. These collaborations underscore the company's commitment to scientific rigor and its strategy to leverage external expertise in advancing its regenerative medicine pipeline.

What Products and Services Does BRTX Offer?

• Develops regenerative medicine products and therapies using cell and tissue protocols.
• Primarily focuses on therapies involving adult stem cells.
• Advances BRTX-100, a lead cell therapy candidate for disc/spine disease, which completed Phase 1 trials.
• Develops ThermoStem, a cell-based therapy in preclinical stage for obesity and metabolic disorders.
• BRTX-100 is formulated from autologous cultured mesenchymal stem cells from the patient's bone marrow.
• ThermoStem utilizes brown adipose derived stem cells to generate brown adipose tissue.
• Provides an investigational curved needle device for precise delivery of therapeutics to the spine and discs.
• Engages in research and development agreements with major pharmaceutical companies like Pfizer and Rohto.

How Does BRTX Make Money?

• Currently, the company's business model is primarily focused on research and development, funded through capital raises and potential milestone payments from partnerships.
• Future revenue generation is anticipated from the commercialization and sales of its lead cell therapy candidate, BRTX-100, upon successful clinical development and regulatory approval.
• Another future revenue stream is expected from the commercialization of its ThermoStem program, targeting obesity and metabolic disorders, if it successfully advances through clinical stages.
• The investigational curved needle device offers potential for direct sales or licensing to other medical device or pharmaceutical companies.
• The company may also generate revenue through licensing agreements, royalties, and expanded research collaborations with pharmaceutical partners.

What Industry Does BRTX Operate In?

BioRestorative Therapies, Inc. operates within the dynamic and rapidly evolving biotechnology sector, specifically carving a niche in regenerative medicine through adult stem cell therapies. This segment of healthcare is characterized by significant innovation, aiming to repair, replace, or regenerate damaged cells, tissues, or organs. The global regenerative medicine market is projected for substantial growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in cell-based therapies. BioRestorative Therapies positions itself by focusing on two high-need areas: disc/spine disease and metabolic disorders. The competitive landscape includes numerous biotech and pharmaceutical companies, ranging from large established players to smaller, specialized firms, all vying for breakthroughs in cell therapy. BioRestorative Therapies differentiates itself through its specific autologous mesenchymal stem cell approach for spinal indications (BRTX-100) and its unique brown adipose derived stem cell strategy for metabolic conditions (ThermoStem), alongside its proprietary delivery device, aiming to capture market share in these specialized therapeutic domains.

Who Are BRTX's Key Customers?

• Currently, key customers include research partners such as Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania.
• Upon commercialization, BRTX-100 would target patients suffering from painful lumbosacral disc disorders seeking non-surgical treatment options.
• For the ThermoStem program, future customers would be patients affected by obesity and various metabolic disorders.
• Healthcare providers, clinics, and hospitals would be end-users and purchasers of approved therapies and the specialized delivery device.
• Other biotechnology or pharmaceutical companies could be potential licensees or purchasers of the investigational curved needle device.

Company Profile

BioRestorative Therapies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melville, US. The company is led by CEO Katharyn Field. BRTX has traded publicly since 2012.

BioRestorative Therapies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

BRTX Valuation & Market Position

With a $3.81M market cap, BioRestorative Therapies, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BRTX's quantitative score of 18/100 is below the peer average of 77/100.

Quarterly Financial Performance: BioRestorative Therapies, Inc.

Revenue for BioRestorative Therapies, Inc. came in at $23K during Mar 2026, a 18.2% improvement versus the preceding quarter. The company recorded a net loss of $2.2M, with diluted EPS of $-2.43. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, BRTX averaged $-5.60 in diluted EPS.

BioRestorative Therapies, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 17.7% above estimates on average.

Wall Street analysts project BioRestorative Therapies, Inc. revenue of about $2.5M for fiscal 2026, with EPS near $-6.60.

BRTX Financials

BRTX Latest News

BRTX Analyst Consensus

BRTX MoonshotScore

Latest BioRestorative Therapies, Inc. Analysis

Common Questions About BRTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources